Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 31;10(1):163-174.
doi: 10.2478/sjcapp-2022-0017. eCollection 2022 Jan.

Psychiatric Diagnoses and Medications in Wolfram Syndrome

Affiliations

Psychiatric Diagnoses and Medications in Wolfram Syndrome

Angela M Reiersen et al. Scand J Child Adolesc Psychiatr Psychol. .

Abstract

Background: Wolfram Syndrome is a rare genetic disorder usually resulting from pathogenic variation in the WFS1 gene, which leads to an exaggerated endoplasmic reticulum (ER) stress response. The disorder is typically characterized by diabetes insipidus, diabetes mellitus, optic nerve atrophy, hearing loss, and neurodegenerative features. Existing literature suggests it may also have psychiatric manifestations.

Objective: To examine lifetime psychiatric diagnoses and medication history in Wolfram Syndrome.

Method: Child, adolescent, and young adult Wolfram Syndrome participants (n=39) were assessed by a child & adolescent psychiatrist to determine best estimate DSM-5 lifetime psychiatric diagnoses as well as psychoactive medication history. In addition, the Child & Adolescent Symptom Inventory-5 (CASI-5) Parent Checklist was used to determine likely psychiatric diagnoses based on symptom counts in Wolfram Syndrome patients (n=33), type 1 diabetes (n=15), and healthy comparison (n=18) groups.

Results: Study participants with Wolfram Syndrome had high lifetime rates of anxiety disorders (77%). Also, 31% had an obsessive-compulsive spectrum disorder, 33% had a mood disorder, 31% had a neurodevelopmental or disruptive behavior disorder, and 31% had a sleep-wake disorder. More than half of Wolfram Syndrome participants had taken at least one psychoactive medication, and one third had taken at least one selective serotonin reuptake inhibitor (SSRI). Some individuals reported poor response to sertraline but better response after switching to another SSRI (fluoxetine or citalopram). In general, people with Wolfram Syndrome often reported benefit from psychotherapy and/or commonly used psychoactive medications appropriate for their psychiatric diagnoses.

Conclusions: Wolfram Syndrome may be associated with elevated risk for anxiety and obsessive-compulsive spectrum disorders, which seem generally responsive to usual treatments for these disorders.

Keywords: Anxiety; ER stress; Obsessive Compulsive Disorder; Psychiatry; Wolfram Syndrome; medication.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Lifetime Psychiatric Severity Score Distribution. Score Interpretation: 0 = Few or no symptoms; 1 = Mild symptoms, little or no impairment; 2= Mild symptoms, some impairment; 3= Moderate symptoms, clear impairment; 4= Severe symptoms, clear impairment (see methods for more detailed description). Numbers above each bar are the percentage of Wolfram Syndrome participants with the indicated lifetime severity level as of the most recent clinic visit.

Similar articles

  • Prescription of Controlled Substances: Benefits and Risks.
    Preuss CV, Kalava A, King KC. Preuss CV, et al. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
  • The Black Book of Psychotropic Dosing and Monitoring.
    DeBattista C, Schatzberg AF. DeBattista C, et al. Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
  • WFS1 Spectrum Disorder.
    Barrett T, Tranebjærg L, Gupta R, McCarthy L, Rendtorff ND, Williams D, Wright B, Dias R. Barrett T, et al. 2009 Feb 24 [updated 2022 Dec 1]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2009 Feb 24 [updated 2022 Dec 1]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 20301750 Free Books & Documents. Review.
  • Parent training interventions for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 5 to 18 years.
    Zwi M, Jones H, Thorgaard C, York A, Dennis JA. Zwi M, et al. Cochrane Database Syst Rev. 2011 Dec 7;2011(12):CD003018. doi: 10.1002/14651858.CD003018.pub3. Cochrane Database Syst Rev. 2011. PMID: 22161373 Free PMC article.
  • Pharmacotherapy for anxiety and comorbid alcohol use disorders.
    Ipser JC, Wilson D, Akindipe TO, Sager C, Stein DJ. Ipser JC, et al. Cochrane Database Syst Rev. 2015 Jan 20;1(1):CD007505. doi: 10.1002/14651858.CD007505.pub2. Cochrane Database Syst Rev. 2015. PMID: 25601826 Free PMC article.

Cited by

References

    1. Minton JA, Rainbow LA, Ricketts C, Barrett TG. Wolfram syndrome. Rev Endocr Metab Disord. 2003;4(1):53–9. - PubMed
    1. Rigoli L, Bramanti P, Di Bella C, De Luca F. Genetic and clinical aspects of Wolfram syndrome 1, a severe neurodegenerative disease. Pediatr Res. 2018;83(5):921–929. - PubMed
    1. Yamada T, Ishihara H, Tamura A, Takahashi R, Yamaguchi S, Takei D, Tokita A, Satake C, Tashiro F, Katagiri H, Aburatani H, Miyazaki J, Oka Y. WFS1-deficiency increases endoplasmic reticulum stress, impairs cell cycle progression and triggers the apoptotic pathway specifically in pancreatic beta-cells. Hum Mol Genet. 2006;15(10):1600–9. - PubMed
    1. Altpere A, Raud S, Sütt S, Reimets R, Visnapuu T, Toots M, Vasar E. Mild stress induces brain region-specific alterations of selective ER stress markers’ mRNA expression in Wfs1-deficient mice. Behav Brain Res. 2018;352:94–98. - PubMed
    1. Shrestha P, Mousa A, Heintz N. Layer 2/3 pyramidal cells in the medial prefrontal cortex moderate stress induced depressive behaviors. eLife. 2015;4:e08752. - PMC - PubMed

LinkOut - more resources